Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $225 from $210 and keeps an Overweight rating on the shares. The firm has increased estimates following “the strong beat,” but did not flow all the Q2 upside through to 2026 given uncertainty around the path forward for exchanges, the analyst tells investors in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare: Strategic Focus and Financial Performance Drive Buy Rating
- Tenet Healthcare Reports Strong Q2 2025 Earnings, Raises Outlook
- Tenet Healthcare’s Earnings Call Highlights Robust Growth
- Strong Financial Performance and Strategic Positioning Support Buy Rating for Tenet Healthcare